[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pet--ct\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pet--ct":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,46,74,102,124,147,177,207,229],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100628228","dll3-targeted-petct-in-neuroendocrine-carcinoma-100628228",false,"NCT07458906","DLL3-Targeted PET\u002FCT in Neuroendocrine Carcinoma","Delta-like Protein 3 (DLL3)- Targeted PET Imaging in Neuroendocrine Carcinoma","Inclusion Criteria:\n\n* Adult patients (aged 18 years or older);\n* Patients with suspected, newly diagnosed, and previously treated neuroendocrine carcinoma(supporting evidence may include imaging findings and pathology report);\n* Serum ProGRP or NSE level ≥ 3 times the upper limit of normal;\n* Patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.\n* Estimated life expectancy of more than 3 months, as assessed by the investigator, and ability to comply with study procedures and scheduled visits;\n\nExclusion Criteria:\n\n* The inability or unwillingness of the research participant or legal representative to provide written informed consent.\n* Inability to complete PET\u002FCT imaging.","ALL","18 Years","80 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"NA","The objective of the study is to evaluate the diagnostic value of DLL3-targeted PET\u002FCT in patients with suspected or histologically confirmed neuroendocrine carcinoma, and to compare with conventional imaging modalities.",[27,28,29],"DLL3-expressing Tumors","PET \u002F CT","Neuroendocrine Cancer",[31,32,29],"DLL3-expressing tumors","PET\u002FCT","RECRUITING","2026-03-04",{"date":36,"type":37},"2026-03-09","ACTUAL",{"date":39,"type":37},"2025-12-01",{"date":41,"type":21},"2026-12-31",{"name":43,"class":44},"The First Affiliated Hospital of Xiamen University","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":4},"100626950","pd-l1-targeting-peptide-probe-for-pet-imaging-of-solid-tumor-100626950","NCT07442292","PD-L1 Targeting Peptide Probe for PET Imaging of Solid Tumor","PD-L1 Targeting Peptide Probe 68Ga-cPP-BCH for PET Imaging of Solid Tumor","Inclusion Criteria:\n\n1. Aged 18-75, male and female, with ECOG score of 0 or 1;\n2. Subjects with lung cancer, melanoma, or other solid tumors scheduled for immunotherapy or combined immunotherapy;\n3. underwent PD-L1 IHC examination before therapy;\n4. The expected survival was more than 26 weeks;\n5. Blood routine test, liver and kidney function meet the following standards: blood routine: WBC \\>= 4.0 x 10\\^9\u002FL or neutrophil \\>= 1.5 x 10\\^9\u002F:, PLT \\>= 100 x 10\\^9 \u002F L, Hb \\>= 90g \u002F L; Pt or APTT \\\u003C= 1.5 upper limit of normal value; liver and kidney function: total bilirubin \\\u003C= 1.5 x ULT (upper limit of normal value), ALT \u002F AST \\\u003C= 2.5 upper limit of normal value or \\\u003C= 5 x ULT (subject with liver metastasis), ALP \\\u003C= 2.5 upper limit of normal value (if bone metastasis or liver metastasis exists, ALP \\\u003C= 4.5 upper limit of normal value); BUN \\\u003C= 1.5 x ULT, SCR \\\u003C= 1.5 x ULT;\n6. According to RECIST1.1, there was at least one measurable target lesion;\n7. Understand and sign informed consent voluntarily with good compliance.\n\nExclusion Criteria:\n\n1. The function of liver and kidney was seriously abnormal;\n2. Preparation for pregnant, pregnant and lactating women;\n3. Inability to lie flat for half an hour;\n4. Suffering from claustrophobia or other mental disorders;\n5. Other researchers considered it unsuitable to participate in the trial.","75 Years",{"count":55,"type":21},40,"OBSERVATIONAL","The objective of this study is to construct a noninvasive approach using radiolabbled peptide 68Ga-cPP-BCH PET\u002FCT to detect the PD-L1 expression of tumor lesion in patients with lung cancer, melanoma and other solid tumor to identify patients benefiting from anti-PD-(L)1 treatment.",[59,60,61,62,63,28],"Lung Cancer (NSCLC)","Lung Cancer (SCLC)","Melanoma (Skin Cancer)","Melanoma Metastatic","PD-L1","NOT_YET_RECRUITING","2026-03-03",{"date":67,"type":37},"2026-03-05",{"date":69,"type":21},"2026-02",{"date":71,"type":21},"2027-06",{"name":73,"class":44},"Peking University Cancer Hospital & Institute",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":84,"conditions":85,"keywords":88,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":45},"100622617","evaluation-of-the-diagnostic-efficacy-of-a-v6fap-targeting-heterodimeric-probe-in-patients-with-malignant-solid-tumors-100622617","NCT07385950","Evaluation of the Diagnostic Efficacy of a αvβ6\u002FFAP-Targeting Heterodimeric Probe in Patients With Malignant Solid Tumors","Evaluation of Diagnostic Efficacy of a αvβ6\u002FFAP-Targeting Heterodimeric Probe in Patients With Malignant Solid Tumors: An Open-Label, Single-Arm, Single-Center Study","Inclusion Criteria:\n\n1. Voluntarily provide written informed consent.\n2. Age ≥ 18 years.\n3. Newly diagnosed with a clinically\u002Fradiologically suspected or pathologically confirmed malignant solid tumor, or with suspected recurrence after prior treatment.\n4. Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 or 1.\n5. Life expectancy \\> 6 months.\n6. Participants of childbearing potential and their partners must agree to use highly effective contraception for 6 months following the last dose of the investigational agent.\n\nExclusion Criteria:\n\n1. Prior radioisotope therapy within an interval less than 10 times the physical half-life of the respective radionuclide before study administration.\n2. Concurrent participation in any other interventional clinical trial.\n3. Known allergy or hypersensitivity to the investigational agent or any of its excipients.\n4. Inability to lie still for the duration of the PET scan or any condition contraindicating PET imaging.\n5. Pregnancy or lactation.\n6. Any other condition that, in the investigator's judgment, would compromise participant safety or study integrity.","90 Years",{"count":83,"type":21},100,"Malignant tumors pose a grave threat to human health and impose a substantial burden on society. Molecular imaging, which enables non-invasive, in vivo visualization of biological processes at the molecular level, is crucial for early diagnosis and treatment monitoring, thereby improving clinical management. Currently, molecular probes targeting fibroblast activation protein (FAP) and integrin αvβ6, such as ⁶⁸Ga-labeled FAPI and ⁶⁸Ga-Trivehexin, have shown promise in oncologic PET imaging, yet each has limitations.\n\nFAP is predominantly overexpressed in cancer-associated fibroblasts within the tumor stroma, with minimal expression in normal tissues. However, radiotracers like ⁶⁸Ga-FAPI often exhibit physiological uptake in normal organs (e.g., salivary glands, pancreas, uterus), leading to elevated background signals and potentially reduced diagnostic contrast. Conversely, integrin αvβ6 is primarily expressed on tumor cell surfaces and is upregulated in many malignancies. Nonetheless, probes like ⁶⁸Ga-Trivehexin suffer from high renal retention with slow clearance and notable physiological gastrointestinal uptake, resulting in suboptimal target-to-background ratios and compromised image quality.\n\nGiven the complementary expression profiles of FAP (stroma) and integrin αvβ6 (tumor cells), we hypothesize that a bispecific molecular probe capable of simultaneously engaging both targets could achieve superior tumor targeting through a synergistic \"dual-lock\" mechanism. This prospective exploratory clinical trial aims to evaluate the diagnostic efficacy and safety of a novel bispecific probe, named ⁶⁸Ga-B6FA-01, in patients with malignant solid tumors. The ultimate goal is to develop a superior imaging strategy for early and precise tumor diagnosis, treatment response assessment, and personalized therapeutic decision-making.",[28,86,87],"Solid Tumors","Adult",[89,90,91,92],"integrin αVβ6","FAP","PET imaging","Diagnostic efficacy","2026-01-26",{"date":95,"type":37},"2026-02-04",{"date":97,"type":21},"2026-01-15",{"date":99,"type":21},"2028-12-31",{"name":101,"class":44},"Zhongnan Hospital",{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":109,"enrollmentInfo":110,"targetDuration":112,"studyType":56,"phases":4,"briefSummary":113,"conditions":114,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":4},"100603479","precise-guidance-of-adaptive-radiotherapy-for-nasopharyngeal-carcinomar-100603479","NCT07137052","Precise Guidance of Adaptive Radiotherapy for Nasopharyngeal Carcinomar","A Prospective Multi-center Clinical Study on Precise Guidance of Adaptive Radiotherapy for Nasopharyngeal Carcinomar by Multi-dimensional Molecular Imaging","Inclusion Criteria:\n\n1. Any sex; age 18-70 years.\n2. Histologically confirmed non-keratinizing nasopharyngeal carcinoma (World Health Organization (WHO) type II or III).\n3. Clinical stage I-IVA (American Joint Committee on Cancer (AJCC)\u002FUnion for International Cancer Control (UICC) 8th edition) with no evidence of distant metastasis.\n4. Eastern Cooperative Oncology Group (ECOG) performance status 0-1.\n5. No prior anti-tumor treatment for nasopharyngeal carcinoma, including radiotherapy, chemotherapy, immunotherapy, or biologic therapy.\n6. No contraindications to radiotherapy or chemotherapy.\n7. Adequate major organ function as defined below:\n\n   7.1 Hematology: white blood cell (WBC) ≥ 4.0 × 10\\^9\u002FL, absolute neutrophil count (ANC) ≥ 1.5 × 10\\^9\u002FL, platelet count ≥ 100 × 10\\^9\u002FL, hemoglobin ≥ 90 g\u002FL (no blood transfusion or blood products within 14 days and no use of granulocyte colony-stimulating factor (G-CSF) or other hematopoietic growth factors to correct counts);\n\n   7.2 Biochemistry: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × upper limit of normal (ULN); blood urea nitrogen (BUN) and serum creatinine ≤ 1.5 × ULN, or creatinine clearance ≥ 60 mL\u002Fmin calculated by the Cockcroft-Gault formula.\n8. Participant voluntarily agrees to join the study, signs informed consent, has good compliance, and is able to attend follow-up.\n\nExclusion Criteria:\n\n1. Pathological type of keratinizing squamous cell carcinoma or basaloid squamous cell carcinoma.\n2. History of or concurrent other active (unresolved) malignant tumors, except for previously cured basal cell carcinoma of the skin, carcinoma in situ of the cervix, or superficial bladder cancer.\n3. Currently participating in another clinical trial.\n4. Pregnant or breastfeeding women.\n5. Uncontrolled cardiovascular disease, including ≥ Grade II myocardial ischemia or myocardial infarction, uncontrolled cardiac arrhythmias (including corrected QT (QTc) interval ≥ 470 ms); heart failure New York Heart Association (NYHA) class III-IV, or left ventricular ejection fraction (LVEF) \\\u003C 50% on echocardiography; or myocardial infarction within the past year.\n6. Other severe comorbidities such as uncontrolled hypertension, severe cerebrovascular disease, severe renal disease, uncontrolled diabetes mellitus, or other chronic wasting diseases.\n7. History of substance or alcohol abuse, psychiatric illness, or lack of full or having limited civil capacity.\n8. In the investigator's judgment, other familial or social factors that could force premature withdrawal from the study, or other conditions likely to affect participant safety or the collection of trial data.","70 Years",{"count":111,"type":21},732,"3 Years","This is an observational cohort study designed to (1) evaluate whether Gallium-68 (68Ga)-labeled fibroblast activation protein inhibitor ligand LM3 (68Ga-FAPI-LM3) positron emission tomography\u002Fcomputed tomography (PET\u002FCT) improves the accuracy of nasopharyngeal carcinoma (NPC) staging, and (2) determine whether Gallium-68-labeled programmed death-ligand 1 (68Ga-PD-L1) PET\u002FCT imaging parameters can provide early prediction of response to neoadjuvant immunotherapy. The study will assess the sensitivity and specificity of each tracer for staging and for predicting therapeutic response, analyze changes in tumor uptake parameters on 68Ga-FAPI-LM3 and 68Ga-PD-L1 PET\u002FCT before and after treatment, and compare treatment efficacy and survival outcomes between patients with different degrees of residual PET uptake and between those who did and did not receive neoadjuvant immunotherapy. The primary question it aims to answer is:\n\nDoes 68Ga-FAPI-LM3 PET\u002FCT improve the accuracy of NPC staging, and can 68Ga-PD-L1 PET\u002FCT imaging parameters provide an early prediction of response to neoadjuvant immunotherapy?\n\nParticipants will be patients with biopsy-proven nasopharyngeal carcinoma who undergo 68Ga-FAPI-LM3 and\u002For 68Ga-PD-L1 PET\u002FCT as part of clinical care or a research protocol. Tumor uptake metrics (e.g., maximum standardized uptake value (SUVmax), mean standardized uptake value (SUVmean), metabolic\u002Fvolumetric indices) will be measured pre- and post-treatment; diagnostic performance (sensitivity, specificity) and associations between uptake changes and clinical outcomes (response rates, progression-free and overall survival) will be calculated.",[115,28],"Nasopharyngeal Carcinoma (NPC)","2025-09-16",{"date":118,"type":37},"2025-09-17",{"date":120,"type":21},"2025-09-30",{"date":122,"type":21},"2029-01-30",{"name":43,"class":44},{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":128,"acronym":4,"eligibilityCriteria":129,"healthyVolunteers":130,"sex":16,"minAge":17,"maxAge":131,"enrollmentInfo":132,"targetDuration":4,"studyType":22,"phases":134,"briefSummary":135,"conditions":136,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":4},"100601721","study-of-melanoma-resistant-pet-monitoring-based-on-key-rate-limiting-enzymes-for-fatty-acid-metabolism-in-healthy-volunteers-100601721","NCT07114172","Study of Melanoma-Resistant PET Monitoring Based on Key Rate-limiting Enzymes for Fatty Acid Metabolism in Healthy Volunteers","Inclusion Criteria:\n\n* Age: 18 to 65 years old (including the boundary values); Gender: Male or female; Weight: Male weight ≥ 50 kg, female weight ≥ 45 kg, and body mass index (BMI = weight (kg) \u002F height² (m²)) within the range of 18.0 to 28.0 kg\u002Fm² (including boundary values); Participants must fully understand and voluntarily participate in this experiment and sign an informed consent form.\n\nExclusion Criteria:\n\n* Individuals who cannot tolerate intravenous administration (e.g., those with a history of fainting from needles or blood); Individuals with alcohol allergies; Pregnant or breastfeeding women; Individuals with severe diseases of the heart, kidneys, lungs, blood vessels, nervous system, or mental health, immune deficiency diseases, or hepatitis\u002Fcirrhosis; Individuals whom the investigator deems unsuitable for or unable to complete PET or other imaging examinations for special reasons; Other circumstances deemed by the investigator to be unsuitable for participation in this study.",true,"65 Years",{"count":133,"type":21},15,[24],"This is a small-sample safety study involving 15 healthy volunteers who were divided into groups and underwent 68Ga-ACC-DE, 68Ga-FASN-DE, and 68Ga-ACLY-DE PET\u002FCT imaging for safety, biodistribution, and radiation dosimetry assessments, laying the foundation for subsequent studies on the efficacy of resistance monitoring in melanoma targeted therapy.",[61,137,28],"Health Volunteers","2025-08-08",{"date":140,"type":37},"2025-08-11",{"date":142,"type":21},"2025-08-15",{"date":144,"type":21},"2025-10-15",{"name":146,"class":44},"Xijing Hospital",{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":153,"eligibilityCriteria":154,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":155,"targetDuration":157,"studyType":56,"phases":4,"briefSummary":158,"conditions":159,"keywords":162,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":45},"100586214","to-evaluate-transport-safety-between-different-scanning-methods-for-patients-in-the-intensive-care-unit-icu-100586214","NCT06912464","To Evaluate Transport Safety Between Different Scanning Methods for Patients in the Intensive Care Unit (ICU)","Comparative Safety Analysis: PET vs. CT Scans During Intensive Care Admission","CASA","Inclusion Criteria:\n\n* Patients receiving PET\u002FCT during ICU admission (any indication)\n* Patients undergoing CT Thorax\u002FAbdomen (matched cohort)\n\nExclusion Criteria:\n\n* CT-scan for any acute indication (acute danger to vital parameters).\n* CT-Cerebrum\n* Registrion in the dutch Objection to medical research registry.",{"count":156,"type":21},208,"2 Days","The goal of this study is to assess how safe it is for critically ill patients in the Intensive Care Unit (ICU) to undergo a PET scan. A PET scan is a type of medical imaging used to help determine why a patient is sick. It is similar to a CT scan but involves a small amount of radioactivity to highlight areas of concern in the body.\n\nFor a PET scan, patients need to be transported from the ICU to the scanning room, which can be risky because ICU patients are often very fragile. After a patient gets the PET scan injection, their body gives off a small amount of radiation for a short time. Because of this, doctors and nurses have to keep some distance to protect themselves. This means they keep an eye out for the patient from a bit further away than normal. This makes the procedure slightly riskier, especially for very sick patients.\n\nThis study aims to answer the question:\n\nIs getting a PET scan riskier for ICU patients than a regular CT scan?\n\nAll patients in this study will continue to receive their usual critical care. Researchers will closely monitor the scanning process to evaluate its safety.\n\nPET scans are already widely used to detect cancer, but new advancements may allow us to use them more often to diagnose infections. Before this can become routine practice, we need to ensure that PET scanning is just as safe as other commonly used imaging techniques. This study will assess all ICU patients undergoing a PET scan-regardless of the reason for the scan-to determine how safe the procedure is in critically ill individuals.",[160,28,161],"Transportation of Patients","Intensive Care Medicine",[163,161,164,165,32,166,167],"Intrahospital transport (IHT)","ICU","PET","Safety","CT","2025-03-31",{"date":170,"type":37},"2025-04-04",{"date":172,"type":21},"2025-04-01",{"date":174,"type":21},"2027-04-01",{"name":176,"class":44},"University Medical Center Groningen",{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":4,"eligibilityCriteria":183,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":184,"targetDuration":4,"studyType":22,"phases":186,"briefSummary":187,"conditions":188,"keywords":193,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":45},"100586103","68ga-fapi-46-in-staging-of-pancreatic-adenocarcinoma-100586103","NCT06911021","68Ga-FAPI-46 in Staging of Pancreatic Adenocarcinoma","68Ga-FAPI-46 PET\u002FCT for Tumor Fibroblast Imaging to Refine Tumor Assessment and Therapeutic Strategies of Pancreatic Adenocarcinoma","Inclusion Criteria:\n\n* Age ≥18 years.\n* Karnofsky index ≥80%.\n* Operable or operable borderline tumor after neoadjuvant chemotherapy response\n* Planned surgical tumor resection.\n* SOC imaging (ceCT and MRI) performed as pre-surgery exams.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding.\n* Claustrophobia.\n* Severe renal insufficiency (GFR\\\u003C30 mL\u002Fmin\u002F1.73m²).\n* Liver enzymes (ALAT, ASAT \\>5× the upper limit).\n* Bilirubin \\>3× the upper limit.\n* Hemoglobin \\\u003C8 g\u002FdL.\n* Absolute neutrophil count \\\u003C1000\u002Fmm³.\n* Platelets \\\u003C75,000\u002FµL.\n* Inability to give informed consent or follow study procedures.\n* The patient refuses to receive information regarding incidental findings.",{"count":185,"type":21},20,[24],"This clinical study investigates the use of a new imaging technique called 68Ga-FAPI-46 PET\u002FCT in people with pancreatic ductal adenocarcinoma (PDAC), a type of cancer known for its rapid progression, late diagnosis, and poor survival rate. One of the main challenges with pancreatic cancer is that standard images like MRI and CT, while helpful, are not always able to clearly show how far the cancer has spread or where exactly the tumor ends. This can make surgery and treatment planning more difficult and less precise.\n\nThe new image technique being studied, 68Ga-FAPI-46 PET\u002FCT, works by injecting a small and safe amount of a radioactive substance into a vein. This substance travels through the body and attaches to a specific protein called FAP, which is found in large amounts in the tissue that surrounds many pancreatic tumors. By sticking to this protein, the tracer highlights not only the tumor but also the surrounding area that may be affected by the cancer. This results in very detailed images that may show the tumor more clearly than other techniques.\n\nEach participant in the study will receive a single injection of the tracer, and about an hour later they will have the PET\u002FCT scan. The scan itself is quick, painless, and non-invasive, and takes about 20 minutes. A few days later, participants will receive a follow-up phone call to check if they experienced any side effects, though previous studies with over 1,000 people have shown the tracer to be very safe.\n\nThe purpose of the study is to find out whether this new technique provides more useful and accurate information than the standard images currently used. It may help better detect the size of the tumor, see if it has spread to other parts of the body, and give doctors a clearer idea of how to plan surgery. This could make it easier to remove the tumor completely and choose the most effective treatment for each patient.\n\nThis pilot study is being conducted at Lausanne University Hospital (CHUV) with 20 adult participants over two years. CHUV is the first hospital in Switzerland to offer this kind of scan. If the study is successful, this scan may become a regular part of care for people with pancreatic cancer and could also be used in other cancers in the future.",[189,28,190,191,192],"Pancreatic Adenocarcinoma","FAPI","Surgical Oncology","Molecular Imaging",[194,195,196,197,198],"Novel imaging in pancreatic cancer","Fibroblast activation protein imaging","Cancer-associated fibroblasts","PET\u002FCT and pancreatic tumor","Tumor microenvironment imaging","2025-03-28",{"date":170,"type":37},{"date":202,"type":21},"2025-05-01",{"date":204,"type":21},"2027-12-31",{"name":206,"class":44},"Centre Hospitalier Universitaire Vaudois",{"id":208,"slug":209,"hasResults":11,"nctId":210,"briefTitle":211,"officialTitle":212,"acronym":4,"eligibilityCriteria":213,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":53,"enrollmentInfo":214,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":216,"conditions":217,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":227,"locationsCount":45},"100564001","the-application-value-of-68ga-grazytracer-pet-in-immunotherapy-for-stage-iii-non-small-cell-lung-cancer-100564001","NCT06623487","The Application Value of 68Ga-grazytracer PET in Immunotherapy for Stage III Non-small-cell Lung Cancer","The Application Value of 68Ga-grazytracer PET in Immunotherapy for Stage III Non-small-cell Lung Cancer: a Prospective, Observationa Trial","Inclusion Criteria:\n\n1. Patients with stage III NSCLC, after assessment according to clinical guidelines, require neoadjuvant immunotherapy;\n2. Fully-informed written consent obtained from patients;\n3. Patient ability to comply with protocol requirements;\n4. Age 18-75 years;\n5. Life expectancy of at least 6 months.\n\nExclusion Criteria:\n\n1. Patients with serious diseases that the investigator deems unsuitable for participation in the clinical study. Such as severe cardiopulmonary insufficiency, severe bone marrow suppression, severe hepatic or renal insufficiency, etc;\n2. Intestinal perforation, complete intestinal obstruction;\n3. Patients with uncontrolled diabetes mellitus or a fasting blood glucose value of ≥11 mmol\u002FL on the day of the test;\n4. Pregnant women and women who are potentially pregnant, as well as nursing mothers;\n5. Patients with poor compliance.",{"count":215,"type":21},30,"Neoadjuvant immunotherapy can significantly improve the pathological complete response (pCR) and major pathological response (MPR) rates in resectable stage III non-small cell lung cancer (NSCLC), and extend the event-free survival (EFS). However, the current means for evaluating its efficacy are limited. This study aims to utilize the convenient and non-invasive 68Ga-grazytracer PET imaging to detect the aggregation of CD8+ T cells in target lesions after neoadjuvant immunotherapy for stage III NSCLC, and to assess its value in efficacy monitoring, providing valuable information for clinical treatment decisions.",[218,28,219],"Carcinoma, Non-Small-Cell Lung","Neoadjuvant Immunotherapy","2024-09-29",{"date":222,"type":37},"2024-10-02",{"date":224,"type":37},"2024-07-19",{"date":226,"type":21},"2027-07-31",{"name":228,"class":44},"Ruijin Hospital",{"id":230,"slug":231,"hasResults":11,"nctId":232,"briefTitle":233,"officialTitle":234,"acronym":4,"eligibilityCriteria":235,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":53,"enrollmentInfo":236,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":237,"conditions":238,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":241,"lastUpdatePostDateStruct":242,"startDateStruct":244,"completionDateStruct":246,"leadSponsor":248,"locationsCount":45},"100562822","68ga-grazytracer-pet-assists-in-diagnosing-pseudoprogression-following-immunotherapy-in-lung-cancer-100562822","NCT06608160","68Ga-grazytracer PET Assists in Diagnosing Pseudoprogression Following Immunotherapy in Lung Cancer.","68Ga-grazytracer PET\u002FCT Assists in Diagnosing Pseudoprogression Following Immunotherapy in Lung Cancer: a Prospective, Observational Study.","Inclusion Criteria:\n\n1. Lung cancer patients who develope lesion enlargement and\u002For new lesions after treatment with immune checkpoint inhibitors;\n2. Pseudoprogression cannot be ruled out in clinical practice;\n3. Lung cancer confirmed by pathology or cytology, regardless of pathological type;\n4. Fully-informed written consent obtained from patients;\n5. Patient ability to comply with protocol requirements;\n6. Age 18-75 years;\n7. Life expectancy of at least 6 months.\n\nExclusion Criteria:\n\n1. Patients with serious diseases that the investigator deems unsuitable for participation in the clinical study. Such as severe cardiopulmonary insufficiency, severe bone marrow suppression, severe hepatic or renal insufficiency, etc;\n2. Intestinal perforation, complete intestinal obstruction;\n3. Active phase of hepatitis B；\n4. Pregnant women and women who are potentially pregnant, as well as nursing mothers;\n5. Patients with poor compliance.",{"count":215,"type":21},"Currently, there are limited methods available in clinical practice to distinguish pseudoprogression after immunotherapy. Most patients rely on follow-up observations to monitor the disease, which does not meet clinical needs. 68Ga-grazytracer is a novel imaging agent targeting granzyme B. By detecting the concentration of granzyme B, it reflects the localization of cytotoxic T cells in the tumor region and their potential ability to kill tumor cells. This study aims to leverage the simplicity, non-invasiveness, visualization, and semi-quantitative advantages of 68Ga-grazytracer PET imaging to evaluate its effectiveness and feasibility in diagnosing pseudoprogression.",[28,239,240],"Lung Carcinoma","Immunotherapy","2024-09-19",{"date":243,"type":37},"2024-09-23",{"date":245,"type":37},"2024-06-20",{"date":247,"type":21},"2025-12-31",{"name":228,"class":44}]